KPX Lifescience.Co.Ltd
KPX Lifescience.Co.,Ltd. engages in development, production, and sale of agrochemical raw materials and pharmaceutical intermediates in South Korea and internationally. The company offers raw materials for pharmaceuticals, pesticides, and primary intermediates to the pharmaceutical and agrochemical markets. It also develops EDP-CL, an intermediate for piperacillin-based antibiotics, including N,N… Read more
KPX Lifescience.Co.Ltd - Asset Resilience Ratio
KPX Lifescience.Co.Ltd (114450) has an Asset Resilience Ratio of 7.59% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how KPX Lifescience.Co.Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down KPX Lifescience.Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩3.82 Billion | 7.59% |
| Total Liquid Assets | ₩3.82 Billion | 7.59% |
Asset Resilience Insights
- Limited Liquidity: KPX Lifescience.Co.Ltd maintains only 7.59% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
KPX Lifescience.Co.Ltd Industry Peers by Asset Resilience Ratio
Compare KPX Lifescience.Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 4.82% |
|
DongKoo Bio&Pharma Co. Ltd
KQ:006620 |
Pharmaceuticals | 4.28% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Sam-A Pharm. Co. Ltd
KQ:009300 |
Pharmaceuticals | 34.37% |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040 |
Pharmaceuticals | 5.22% |
|
WooGene B&G Co. Ltd
KQ:018620 |
Pharmaceuticals | 3.35% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 61.00% |
|
EstechPharma Co. Ltd
KQ:041910 |
Pharmaceuticals | 9.64% |
Annual Asset Resilience Ratio for KPX Lifescience.Co.Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for KPX Lifescience.Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 28.65% | ₩12.89 Billion | ₩44.97 Billion | -4.32pp |
| 2023-12-31 | 32.98% | ₩14.45 Billion | ₩43.83 Billion | +6.31pp |
| 2022-12-31 | 26.67% | ₩16.65 Billion | ₩62.43 Billion | +4.57pp |
| 2021-12-31 | 22.10% | ₩15.90 Billion | ₩71.98 Billion | +1.16pp |
| 2020-12-31 | 20.94% | ₩14.83 Billion | ₩70.85 Billion | -3.14pp |
| 2019-12-31 | 24.07% | ₩17.31 Billion | ₩71.89 Billion | +5.27pp |
| 2018-12-31 | 18.80% | ₩13.04 Billion | ₩69.37 Billion | -13.64pp |
| 2017-12-31 | 32.44% | ₩23.67 Billion | ₩72.96 Billion | -2.05pp |
| 2016-12-31 | 34.48% | ₩26.57 Billion | ₩77.06 Billion | +18.98pp |
| 2015-12-31 | 15.50% | ₩10.41 Billion | ₩67.15 Billion | -0.61pp |
| 2014-12-31 | 16.11% | ₩10.70 Billion | ₩66.43 Billion | -- |